CAS: 58579-51-4; 6,7-Dichloro-5,10-Dihydroimidazo[2,1-B]Quinazolin-2(3H)-One Hydrochloride

上下游产品

CAS号68475-42-3 阿那格雷 | CAS号506-68-3 溴化氰 | CAS号70406-92-7 N-(2,3-二氯-6-氨基苄... | CAS号78052-21-8 2,4,5,6-tetrach...

(2-Amino-5,6-Dichloroquinazolin-3(4H)-yl)Acetic Acid Methyl Ester Hydrochloride置于盐酸体系中,用 水 作为反应溶剂,化学反应 1.0H,反应生成 盐酸阿那格雷
参考文献:[de] Verwendung Von 2-Amino-2H-Chinazolin-Derivaten Zur Herstellung Von Therapeutischen Mitteln Use Of 2-Amino-2H-Quinazoline Derivatives For Producing Therapeutic Agents[fr] Utilisation De Derives De 2-Amino-2H-Quinazoline Pour La Preparation De Produits Therapeutiques
标题:[de] Verwendung Von 2-Amino-2H-Chinazolin-Derivaten Zur Herstellung Von Therapeutischen Mitteln Use Of 2-Amino-2H-Quinazoline Derivatives For Producing Therapeutic Agents[fr] Utilisation De Derives De 2-Amino-2H-Quinazoline Pour La Preparation De Produits Therapeutiques
摘要:这项发明涉及使用一般化学式(I)中的2-氨基-2H-喹唑啉衍生物,其中r1代表具有1-5个碳原子的烷基基团,R2,R3,R4和r5分别独立地代表氯或氢原子,以及它们的药用相容盐,用于制备治疗多发性增生性疾病,高血压和支气管扩张的药物.

专利信息

专利号:US-9067944-B2
优先权日:2010-10-21
标题:Process for the preparation of anagrelide and analogues thereof
发明人：MCGEE PAUL
权利人:MCGEE PAUL; SHIRE LLC
摘要:The present invention relates to a novel process for producing anagrelide, 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin 2(3H)-one, or certain analogs thereof. The process of the invention also provides improved processes for producing key intermediates required for the synthesis of anagrelide or certain analogs thereof.

专利号:RU-2042678-C1
优先权日:1991-05-22
标 题:Method of synthesis of 6,7-dichloro-1,5-dihydroimidazo-[2,1-b]-quinazoline-2-(3h)-one, intermediates for their synthesis and a method of their synthesis

专利号:WO-2024180371-A1
优先权日:2023-03-02
标题:Synthesis and purification of the active pharmaceutical ingredient of anagrelide hydrochloride and all its intermediates
发明人：MOHAMMADI ALI; RAMAZANI ALI; AGHAHOSSEINI HAMIDEH
权利人:MOHAMMADI ALI
摘要:Anagrelide hydrochloride is a synthetic derivative of benzene used to treat primary thrombocythemia and secondary thrombocytes as well as myeloproliferative disorders. Anagrelide has a unique function, so that it can selectively reduce the number of platelets, without affecting other types of blood cells. In the present invention, all key intermediates and active pharmaceutical ingredients of Anagrelide hydrochloride were synthesized using cheap and available raw materials. In this regard, appropriate, practical and cost-effective methods were used by carefully examining the available synthetic routes to produce all the key intermediates and the active component of Anagrelide. Also, the many and complex stages of separation and purification of products were greatly facilitated by developing simple methods for separation and purification of products, such as the crystallization process or choosing the right combination of washing solvents.